Therakind Sponsors Drug Delivery to Lung Forum 2024
Exhibit Booth #196 -Convenient and effective nasal drug delivery with DriDose® devices
London, England – November 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines announces sponsorship of the Drug Delivery to the Lung (DDL) 2024 forum in Edinburgh, 11-13 December 2024. DDL is a renowned respiratory drug delivery conference that attracts over a thousand participants from around the world working in academia and industry.
Louise Rawcliffe, Chief Operating Officer of Therakind, said: “We are pleased to be exhibiting our DriDose® devices at DDL 2024 and look forward to exchanging knowledge with leading experts in the field. We will be at booth #196- visit us to discuss our latest developments in nasal formulation, development and drug delivery.”
Therakind has a portfolio of dry powder intranasal devices and expertise in formulation development and regulatory strategy. Its DriDose® innovative dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single-use devices and injections. The DriDose® device aims to simplify drug delivery and provide an alternative to nasal sprays, nebulizers, tablets, and injections. DriDose® technology has been validated in a clinical trial and tested with a range of molecules in both in vivo and in vitro settings.
Join us at DDL2024 if you would like to learn more about Therakind’s DriDose® technology, and contact us at: bd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com